52 related articles for article (PubMed ID: 17234016)
1. Economic evaluations of leukemia: a review of the literature.
Kasteng F; Sobocki P; Svedman C; Lundkvist J
Int J Technol Assess Health Care; 2007; 23(1):43-53. PubMed ID: 17234016
[TBL] [Abstract][Full Text] [Related]
2. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.
Pickard AS; Topfer LA; Feeny DH
J Natl Cancer Inst Monogr; 2004; (33):102-25. PubMed ID: 15504922
[TBL] [Abstract][Full Text] [Related]
3. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
4. Economic value of out-of-hospital emergency care: a structured literature review.
Lerner EB; Maio RF; Garrison HG; Spaite DW; Nichol G
Ann Emerg Med; 2006 Jun; 47(6):515-24. PubMed ID: 16713777
[TBL] [Abstract][Full Text] [Related]
5. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML.
Redaelli A; Stephens JM; Laskin BL; Pashos CL; Botteman MF
Expert Rev Anticancer Ther; 2003 Jun; 3(3):311-29. PubMed ID: 12820775
[TBL] [Abstract][Full Text] [Related]
6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
7. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
Vu M; Degeling K; Thompson ER; Blombery P; Westerman D; IJzerman MJ
Eur J Haematol; 2022 Jun; 108(6):469-485. PubMed ID: 35158410
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia.
Gao L; Nguyen D; Lee P
Expert Rev Hematol; 2022 Sep; 15(9):833-847. PubMed ID: 36102163
[TBL] [Abstract][Full Text] [Related]
9. Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia.
Lorenzovici L; Szilberhorn L; Farkas-Ráduly S; Gasparik AI; Precup AM; Nagy AG; Niemann CU; Aittokallio T; Kaló Z; Csanádi M
BioDrugs; 2023 Mar; 37(2):219-233. PubMed ID: 36795353
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluations in shoulder pathologies: a systematic review of the literature.
Kuye IO; Jain NB; Warner L; Herndon JH; Warner JJ
J Shoulder Elbow Surg; 2012 Mar; 21(3):367-75. PubMed ID: 21865060
[TBL] [Abstract][Full Text] [Related]
11. Decision Analysis on the Cost-Effectiveness of Sequential Treatment Strategies for Patients with Chronic Myeloid Leukemia in the United States.
Rochau U; Kluibenschaedl M; Stenehjem D; Kuo KL; Oderda G; Brixner D; Siebert U
Value Health; 2014 Nov; 17(7):A639. PubMed ID: 27202283
[No Abstract] [Full Text] [Related]
12. Standard Costs for Health Economic Evaluations: An International Comparison.
Mostardt S; Sandmann FG; Seidl A; Zhou M; Gerber-Grote AU
Value Health; 2014 Nov; 17(7):A427. PubMed ID: 27201104
[No Abstract] [Full Text] [Related]
13. A Systematic Literature Review of the Economic Burden in Multiple Myeloma.
Rizzo M; Xu Y; Panjabi S; Iheanacho I
Value Health; 2014 Nov; 17(7):A628. PubMed ID: 27202226
[No Abstract] [Full Text] [Related]
14. Systematic Review of Economic Evaluations in Cancerology In Brazil Between 1980 And 2013.
Yuba TY; Decimoni TC; Leandro R; Campolina AG; Soarez P
Value Health; 2014 Nov; 17(7):A661. PubMed ID: 27202405
[No Abstract] [Full Text] [Related]
15. Correction to: How relevant are social costs in economic evaluations? The case of Alzheimer's disease.
Peña-Longobardo LM; Rodríguez-Sánchez B; Oliva-Moreno J; Aranda-Reneo I; López-Bastida J
Eur J Health Econ; 2021 Jul; 22(5):849. PubMed ID: 34032969
[No Abstract] [Full Text] [Related]
16. Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?
Lloyd A; Schofield H; Adlard N
Curr Med Res Opin; 2020 Apr; 36(4):609-611. PubMed ID: 31955617
[No Abstract] [Full Text] [Related]
17. [Introduction to leukemia].
DE LANDSHEERE BC
Belg Tijdschr Geneesk; 1960 Jun; 16():528-30. PubMed ID: 13814840
[No Abstract] [Full Text] [Related]
18. Review on evaluations of currently available blood-culture systems.
Rohner P; Auckenthaler R
Clin Microbiol Infect; 1999 Sep; 5(9):513-529. PubMed ID: 11851703
[No Abstract] [Full Text] [Related]
19. Economic burden associated with acute myeloid leukemia treatment.
Zeidan AM; Mahmoud D; Kucmin-Bemelmans IT; Alleman CJ; Hensen M; Skikne B; Smith BD
Expert Rev Hematol; 2016 Jan; 9(1):79-89. PubMed ID: 26568358
[TBL] [Abstract][Full Text] [Related]
20. Cost of illness and economic burden of chronic lymphocytic leukemia.
Blankart CR; Koch T; Linder R; Verheyen F; Schreyögg J; Stargardt T
Orphanet J Rare Dis; 2013 Feb; 8():32. PubMed ID: 23425552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
